Ascendis Pharma A/S (ASND) Expected to Post Quarterly Sales of $160,000.00

Wall Street analysts forecast that Ascendis Pharma A/S (NASDAQ:ASND) will announce sales of $160,000.00 for the current quarter, according to Zacks. Three analysts have made estimates for Ascendis Pharma A/S’s earnings, with the highest sales estimate coming in at $230,000.00 and the lowest estimate coming in at $20,000.00. Ascendis Pharma A/S reported sales of $510,000.00 during the same quarter last year, which would suggest a negative year over year growth rate of 68.6%. The company is scheduled to announce its next earnings results on Thursday, November 15th.

According to Zacks, analysts expect that Ascendis Pharma A/S will report full-year sales of $1.02 million for the current financial year, with estimates ranging from $100,000.00 to $3.00 million. For the next year, analysts expect that the firm will report sales of $52.22 million, with estimates ranging from $80,000.00 to $156.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that that provide coverage for Ascendis Pharma A/S.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, August 29th. The biotechnology company reported ($0.66) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.03) by $0.37. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.16 million. Ascendis Pharma A/S had a negative return on equity of 49.69% and a negative net margin of 17,641.85%.

Several analysts have recently commented on ASND shares. JPMorgan Chase & Co. raised their target price on Ascendis Pharma A/S from $79.00 to $81.00 and gave the stock an “overweight” rating in a research report on Thursday, August 30th. Stifel Nicolaus decreased their target price on Ascendis Pharma A/S from $85.00 to $81.00 and set a “buy” rating for the company in a research report on Thursday, August 30th. BidaskClub raised Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Friday, August 17th. Zacks Investment Research raised Ascendis Pharma A/S from a “hold” rating to a “strong-buy” rating and set a $72.00 target price for the company in a research report on Tuesday, October 30th. Finally, Credit Suisse Group started coverage on Ascendis Pharma A/S in a research report on Friday. They issued an “outperform” rating and a $80.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Ascendis Pharma A/S has an average rating of “Buy” and a consensus price target of $76.89.

Several large investors have recently made changes to their positions in the stock. Orbimed Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 31.1% during the second quarter. Orbimed Advisors LLC now owns 4,413,291 shares of the biotechnology company’s stock worth $293,572,000 after acquiring an additional 1,045,976 shares in the last quarter. FMR LLC raised its holdings in shares of Ascendis Pharma A/S by 24.3% during the third quarter. FMR LLC now owns 4,152,262 shares of the biotechnology company’s stock worth $294,230,000 after acquiring an additional 812,468 shares in the last quarter. Alliancebernstein L.P. raised its holdings in shares of Ascendis Pharma A/S by 2.7% during the third quarter. Alliancebernstein L.P. now owns 714,366 shares of the biotechnology company’s stock worth $50,620,000 after acquiring an additional 19,039 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Ascendis Pharma A/S by 5.1% during the third quarter. BlackRock Inc. now owns 460,961 shares of the biotechnology company’s stock worth $32,663,000 after acquiring an additional 22,172 shares in the last quarter. Finally, FIL Ltd raised its holdings in shares of Ascendis Pharma A/S by 226.5% during the third quarter. FIL Ltd now owns 113,118 shares of the biotechnology company’s stock worth $8,016,000 after acquiring an additional 78,474 shares in the last quarter. Institutional investors and hedge funds own 93.96% of the company’s stock.

Shares of Ascendis Pharma A/S stock traded down $0.52 during midday trading on Monday, hitting $63.38. The company’s stock had a trading volume of 60,085 shares, compared to its average volume of 137,994. The stock has a market cap of $2.74 billion, a PE ratio of -14.64 and a beta of 0.82. Ascendis Pharma A/S has a 1-year low of $33.50 and a 1-year high of $76.99.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.

Further Reading: Insider Trading – What You Need to Know

Get a free copy of the Zacks research report on Ascendis Pharma A/S (ASND)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply